{
    "nctId": "NCT05945732",
    "briefTitle": "DESTINY Breast Respond HER2-low Europe",
    "officialTitle": "A Prospective, Non-interventional Study (NIS) With Trastuzumab Deruxtecan For Patients With HER2-low Expressing Unresectable and/or Metastatic Breast Cancer Accompanied By a Disease Registry of Patients Treated With Conventional Chemotherapy (DESTINY Breast Respond HER2-low Europe)",
    "overallStatus": "RECRUITING",
    "conditions": "Unresectable Breast Cancer, Metastatic Breast Cancer, HER2-low Expressing Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 1350,
    "primaryOutcomeMeasure": "Real World Time to Next Treatment (rwTTNT1) in Participants With HER2-low Expressing Unresectable and/or Metastatic Breast Cancer",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Adult patient (age \u2265 18 years) with histological or cytological confirmed diagnosis of unresectable and/or mBC\n* Documented HER2-low status (IHC1+, IHC2+/ISH-)\n* Patients who have received prior chemotherapy in the metastatic setting or patients who have developed disease recurrence during or within 6 months of completing adjuvant chemotherapy\n* Decision to newly initiate therapy of T-DXd or conventional chemotherapy according to the physicians choice per SmPC\n* Written and signed Informed Consent to participate in the study\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding\n* Patients who at time of data collection for this study are participating in or have participated in an interventional study that remains blinded.\n\nNo specific exclusion criteria are defined, as patients will be treated according to the proposed indication statements in the SmPC.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}